The cytotoxicity of Gal-9 was further assessed toward patient-derived AML cells (see Supplementary Table 1 for patient characteristics), with a clear reduction in cell density in both unsorted, CD34+ AML stem cell and CD34− AML blast populations after treatment with Gal-9 (Fig. 2A). This evidence concerns the gene CD34 and acute myeloid leukemia.